Thursday, Vertex Pharmaceuticals Incorporated (NASDAQ:VTRX) reported second-quarter revenues of $2.65 billion, almost in line with the consensus of estimate of $2.66 billion. Vertex Pharmaceuticals ...

Vertex Pharmaceuticals Inc. raised its sales expectations for the year, citing continued growth of its cystic fibrosis drugs and the launch of its new treatment for sickle cell disease. Vertex now ...

(Reuters) - An influential U.S. drug pricing watchdog raised the price estimate of two experimental gene therapies from Vertex Pharmaceuticals/CRISPR Therapeutics and bluebird bio to as much as $2.05 ...

For Vertex these days, it’s all about the launches of three new products—sickle cell disease gene therapy Casgevy, the company’s fifth cystic fibrosis treatment Alyftrek and its non-opioid pain relief ...

Vertex is severing one of its ties to CRISPR Therapeutics. The big biotech has chosen to opt out of the diabetes gene-edited stem cell therapy it gained through the acquisition of ViaCyte, leaving ...

Vertex Pharmaceuticals has hit a snag in its efforts to follow up non-opioid pain reliever Journavx (suzetrigine). The Boston-based Big Biotech’s sodium channel inhibitor VX-993 failed to outpace ...

The empirical study, started in July and to be conducted over 12 months, is being conducted by TÜV Nord. The selected study site, in Jiangsu province, China, has a subtropical monsoon climate with an ...

July 13 (Reuters) - An influential U.S. drug pricing watchdog raised the price estimate of two experimental gene therapies from Vertex Pharmaceuticals (VRTX.O), opens new tab/CRISPR Therapeutics and ...